Table 1.
Factors predicting 12-month DAS28 remission in a cohort of patients with early arthritis
| Population of general characteristics | |
|---|---|
| Total number of pts with ERA | 481 |
| Total number of pts with VERA | 148 (30.8) |
| Remission after 12 months; n (%) | 165 (34.3) |
| Erosive disease; n (%) | 168 (34.9) |
| csDMARDs only; n (%) | 329 (68.4) |
| bDMARDs; n (%) | 152 (31.6) |
| VERA pts; n (%) | 105 (21.82) |
| csDMARDs only among VERA pts; n (%) | 95 (90.5) |
| bDMARDs among VERA pts; n (%) | 10 (9.5) |
| Multivariate analysis model predicting remission | |
| Variable | OR (95% CI) |
| DAS28 t0 <5.1 | 1.54 (0.94 to 2.51) |
| HAQ t0 <1.5 | 1.29 (0.75 to 2.23) |
| VERA | 2.03 (1.25 to 3.30) |
| Anti-CCP positive | 1.39 (0.94 to 2.07) |
| Erosions t0 | 0.47 (0.29 to 1.08) |
| DMARD in the first 3 months | 1.65 (1.06 to 2.55) |
Significant results are shown in bold.
Analysis restricted to patients with ERA with a baseline moderate–high disease activity (n=481). (Adapted from Gremese et al).8
bDMARDs, biologic disease-modifying anti-rheumatic drugs, CCP, cyclic citrullinated protein; csDMARDs, conventional synthetic-DMARDs, DAS28, disease activity score in 28 joints; ERA, early rheumatoid arthritis; HAQ, health assessment questionnaire; pts, patients; t0, baseline; VERA, very ERA.